Literature DB >> 12577049

Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.

Tatu A Miettinen1, Helena Gylling, Nina Lindbohm, Tatu E Miettinen, Radhakrishnan A Rajaratnam, Heikki Relas.   

Abstract

We studied changes in serum cholestanol and plant sterols (indexes of cholesterol absorption) and cholesterol precursors (indexes of cholesterol synthesis) in response to cholesterol reduction by way of 1 year's treatment with atorvastatin (n = 102) and simvastatin (n = 105) treatments in patients with coronary heart disease. Serum cholesterol levels and ratios of the precursor sterols to cholesterol after 1 year of treatment were reduced in proportion to the pretreatment values (33% +/- 1% by simvastatin and 36% +/- 1% by atorvastatin; P <.01 for difference between groups) for cholesterol; the respective reductions in the precursor sterol:cholesterol ratios were also higher with atorvastatin (50% +/- 2% for lathosterol) than with simvastatin (42% +/- 1%; P <.01 between groups), but the ratio of squalene to cholesterol was increased (17% +/- 5%, P <.001) by atorvastatin. Plant sterol concentrations were gradually increased by atorvastatin but decreased initially by simvastatin. However, their ratios with respect to cholesterol were increased by as much as 82% with atorvastatin and by as much as 39% with simvastatin. In conclusion, effective inhibition of cholesterol synthesis and subsequent reduction in serum cholesterol levels by statins lead to increases in serum plant-sterol levels, probably as a result of reduced biliary secretion and enhanced absorption of these sterols. Because serum plant sterols have been claimed to be involved in the early development of atherosclerosis, the question arises whether continuously increasing serum plant sterols during long-term statin treatment should be prevented by cholesterol malabsorption (eg, by plant stanol ester consumption), especially in subjects with high baseline plant sterol values and effective sterol absorption.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12577049     DOI: 10.1067/mlc.2003.9

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  20 in total

Review 1.  ABCG5/G8 polymorphisms and markers of cholesterol metabolism: systematic review and meta-analysis.

Authors:  Lily Jakulj; Maud N Vissers; Michael W T Tanck; Barbara A Hutten; Frans Stellaard; John J P Kastelein; Geesje M Dallinga-Thie
Journal:  J Lipid Res       Date:  2010-06-25       Impact factor: 5.922

2.  Location, location, location...again.

Authors:  Shailendra B Patel
Journal:  J Lipid Res       Date:  2011-01-04       Impact factor: 5.922

Review 3.  Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.

Authors:  Maria Valeria Catani; Valeria Gasperi; Tiziana Bisogno; Mauro Maccarrone
Journal:  Antioxid Redox Signal       Date:  2017-07-24       Impact factor: 8.401

4.  Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia.

Authors:  Tamio Teramoto; Teruo Sawada; Kazuya Iwamoto; Hiroyuki Daida
Journal:  Curr Ther Res Clin Exp       Date:  2012-02

Review 5.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

6.  Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.

Authors:  Susan G Lakoski; Fang Xu; Gloria L Vega; Scott M Grundy; Manisha Chandalia; Chun Lam; Robert S Lowe; Michael E Stepanavage; Thomas A Musliner; Jonathan C Cohen; Helen H Hobbs
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 7.  Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia: clinical impact of combination therapy with ezetimibe.

Authors:  Tamio Teramoto; Atsunori Kashiwagi; Shun Ishibashi; Hiroyuki Daida
Journal:  Curr Ther Res Clin Exp       Date:  2012-02

8.  Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.

Authors:  Paolo Parini; Ulf Gustafsson; Matt A Davis; Lilian Larsson; Curt Einarsson; Martha Wilson; Mats Rudling; Hiroshi Tomoda; Satoshi Omura; Staffan Sahlin; Bo Angelin; Lawrence L Rudel; Mats Eriksson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-13       Impact factor: 8.311

9.  Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.

Authors:  Thomas M van Himbergen; Nirupa R Matthan; Nancy A Resteghini; Seiko Otokozawa; Masumi Ai; Evan A Stein; Peter H Jones; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2008-11-30       Impact factor: 5.922

10.  Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.

Authors:  Nuntakorn Thongtang; Jianxin Lin; Ernst J Schaefer; Robert S Lowe; Joanne E Tomassini; Arvind K Shah; Andrew M Tershakovec
Journal:  Atherosclerosis       Date:  2012-09-13       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.